Isofol Medical AB ( (SE:ISOFOL) ) has shared an update.
Isofol Medical AB has commenced a clinical phase Ib/II study for its drug candidate arfolitixorin, targeting metastatic colorectal cancer. The study, conducted at Charité – Universitätsmedizin Berlin, aims to evaluate the efficacy and safety of arfolitixorin in combination with standard 5-FU-based therapy. This milestone is part of Isofol’s strategy to bring arfolitixorin closer to market, potentially offering improved treatment options for patients with advanced cancers.
More about Isofol Medical AB
Isofol Medical AB is a research-based biotechnology company focused on improving the prognosis for patients with severe forms of cancer. The company is developing arfolitixorin, a drug candidate intended to enhance the efficacy of first-line treatments for various solid tumors, including colorectal cancer. Isofol Medical AB is publicly traded on Nasdaq Stockholm.
YTD Price Performance: -15.76%
Technical Sentiment Signal: Buy
Current Market Cap: €27.86M
See more insights into ISOFOL stock on TipRanks’ Stock Analysis page.